Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tam, C.
Right arrow Articles by Westerman, D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tam, C.
Right arrow Articles by Westerman, D
Haematologica, Vol 91, Issue 11, 1546-1550
Copyright © 2006 by Ferrata Storti Foundation

Journal Article

Treatment-related myelodysplasia following fludarabine combination chemotherapy

CS Tam, JF Seymour, HM Prince, M Kenealy, M Wolf, EH Januszewicz, and D Westerman

Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia.

Although myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) are rare following fludarabine monotherapy, the risk of these diseases may potentially be increased when fludarabine is combined with cyclophosphamide or mitoxantrone due to synergistic effects on the inhibition of DNA repair. Among 137 patients treated with fludarabine combination regimens, ten patients developed MDS/sAML, including one who had received no other therapy. Six patients had abnormalities of chromosomes 5 and/or 7. The crude rate of MDS/sAML was 2.5% for previously untreated patients, and 9.3% for pretreated patients (p=0.28). The rate of MDS/sAML following fludarabine combination therapy is higher than that previously reported for fludarabine monotherapy.


This article has been cited by other articles:


Home page
 haematolHome page
J. W. Friedberg
Secondary malignancies after therapy of indolent non-Hodgkin's lymphoma
Haematologica, March 1, 2008; 93(3): 336 - 338.
[Full Text] [PDF]

Home page
 haematolHome page
S. Montoto, C. Moreno, E. Domingo-Domenech, C. Estany, A. Oriol, A. Altes, J. Besalduch, C. Pedro, S. Gardella, L. Escoda, et al.
High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma
Haematologica, February 1, 2008; 93(2): 207 - 214.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2006 by the Ferrata Storti Foundation.